Atara Biotherapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on March 2, 2018, reporting events occurring on February 28, 2018. The filing details the execution of an underwriting agreement for a public offering of common stock.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. The primary financial data relates to the proposed capital raise:
- Shares Offered: 4,285,714 shares of common stock.
- Public Offering Price: $35.00 per share.
- Price to Company: $32.90 per share (net of underwriting discounts).
- Expected Gross Proceeds: Approximately $150.0 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 642,857 additional shares.
- Maximum Gross Proceeds: Approximately $172.5 million if the option is fully exercised.
Material Changes
The material change reported is the initiation of a public equity offering. This transaction is expected to significantly increase the company's cash liquidity upon closing, which is anticipated on March 5, 2018, subject to customary conditions.
Outlook, Risks, and Unusual Items
The offering is being made pursuant to an effective registration statement on Form S-3 (No. 333-223262). The Underwriting Agreement includes customary representations, warranties, indemnification obligations, and termination provisions. The filing notes that the agreement's terms are qualified by reference to the full text of the agreement filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 5, 2018).
- Confirm whether the underwriters exercise the 30-day option to purchase the additional 642,857 shares.
- Review the final prospectus supplement for specific use of proceeds and updated financial position.
- Check for any dilution impact on existing shareholders post-closing.